Home » Newsletters » BioWorld Science

BioWorld Science

April 27, 2017

View Archived Issues

Chugai presents highlights of first quarter 2017

Capricor reports 6-month data from phase I/II trial of CAP-1002 for DMD

FDA clears Glenmark's IND for first-in-human study of omalizumab biosimilar GBR-310

European Commission approves Varuby

BioVie signs CRADA for phase IIa study of BIV-201 in refractory ascites

Janssen seeks Japanese approval for bedaquiline for multidrug-resistant pulmonary TB

Lilly initiates phase I study of LY-3321367 in advanced relapsed or refractory solid tumors

Q BioMed and Asdera sign licensing agreement for ASD-002 to treat rare pediatric nonverbal disorder

Phase III trial of intranasal midazolam in seizure clusters meets primary endpoint

FDA agrees on phase III program for inclisiran

Kiadis Pharma files MAA with EMA for ATIR-101 in blood cancers

AstraZeneca returns AZD-9412 rights to Synairgen

MDxHealth and Exact Sciences collaborate in epigenetics and molecular diagnostics

Retrophin initiates phase III study of fosmetpantotenate in patients with PKAN

Final 24-month data presented from the phase II OLE trial of patisiran

Phase III MYSTICOL study results presented for botulinum toxin type B in sialorrhea

Metrion Biosciences and Venomtech collaborate to identify novel ion channel modulators

Preclinical data for a novel tetravalent bispecific antibody, LY-3207447

Boehringer Ingelheim patents RORgamma t antagonists

LegoChem Biosciences reports beta-lactamase inhibitors

NeuroVive Pharmaceutical patent describes NFE2-related factor 2 activators

Proteostasis Therapeutics discloses CFTR channel correctors for cystic fibrosis

Astex and GlaxoSmithKline jointly develop agents for COPD

Roche reports glutamate transporter EAAT3 inhibitors

BeyondSpring enrolling U.S. patients in phase II/III study of plinabulin

Progress in merger of PharmAthene and Altimmune

Evotec, Sanofi describe oral cancer immunotherapeutic agent EVT-801

FDA designates TLC-178 as drug for rare pediatric disease for rhabdomyosarcoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...